RBD 1016
Alternative Names: RBD-1016Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Suzhou Ribo Life Science
- Class Amides; Amino sugars; Antivirals; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Hepatitis-B(Combination therapy, In adults) in China (SC, Injection)
- 21 Aug 2024 Phase-II clinical trials in Hepatitis B in Sweden (SC) (NCT06649266)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in Australia (SC, Injection)